摘要
目的探讨伊立替康联合铂类一线治疗广泛期小细胞肺癌的临床效果及对患者血清水平的影响。方法选择我院收治的120例小细胞肺癌患者为研究对象,随机均分为研究组和对照组,研究组患者应用伊立替康联合铂类一线治疗(IP),对照组患者应用依托泊苷联合铂类治疗(EP),观察患者血清水平及治疗效果。结果研究组患者疗效显著优于对照组(P<0.05),生存期和生存率显著高于对照组(P<0.05),并发症发生率显著低于对照组(P<0.05)。治疗前,两组患者血清水平无明显差异(P>0.05),治疗后,研究组患者血清水平显著优于对照组(P<0.05)。结论伊立替康联合铂类一线治疗小细胞肺癌安全有效。
Objective To investigate the clinical effect of Irinotecan combined with platinum in the first line treatment of broad stage small cell lung cancer and its effect on serum level. Methods A total of 120 cases of small cell lung cancer patients in our hospital as the research objects, were randomly divided into study group and control group. The study group was treated with irinotecan plus platinum as first-line therapy （IP）, while the control group was treated with etoposide combined with platinum treatment （EP）. The serum levels and treatment effects of patients were observed and compared. Results The research results showed that the survival of patients in study group was significantly longer than that of the control group. The survival rate of study group was also significantly higher than that of the control group （P〈0.05）. Patients of the study group had significantly better effects than those of the control group （P〈0.05）. In the study group, the incidence of complications was significantly lower than in the control group （P〈0.05）. Moreover, the serum levels of the two groups showed no significant difference before treatment （P〉0.05）, but after treatment it was significantly better in the study group than in the control group （P〈0.05）. Conclusion Irinotecan was safe and effective in combination with platinum in the first line therapy for small cell lung cancer.
作者
李琛
杨晓光
洪洋
苏菁
冯平
肖丽
温翠玲
LI Chen;YANG Xiaoguang;HONG Yang;SU Jing;FENG Ping;XIAO Li;WEN Cuiling(Department of Respiratory Medicine, the First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, 075000, China;Graduate School of Medical University of Tianjin, 300300, China;Orthopaedics, Second Hospital of Zhangjiakou, Zhangjiakou, Hebei, 075000, China;Graduate School of Hebei North University, Zhangjiakou, Hebei, 075000, China)
出处
《肿瘤药学》
CAS
2018年第2期211-214,共4页
Anti-Tumor Pharmacy
基金
河北省医学科学研究重点课题(20150471)
关键词
伊立替康联合铂类一线治疗
依托泊苷联合铂类治疗
小细胞肺癌
血清水平
Irinotecan combined with Platinum first-line treatment
Treatment of carboplatin combined with platinum
Small cell lung cancer
Serum level
